Intelligence Report · ~15 min read

Osteoporosis · Bisphosphonate Therapeutic Area Assessment

1 signals · 1 insights · 5 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 23, 2026

Confidence

Low Confidence · 55%

Evidence

7 items

Sources

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Osteoporosis · Bisphosphonate integrates 1 signals, 1 executive insights, and 5 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

signalJun 23, 2026
FDA Grants AP Status for Teva's Risedronate Sodium Supplement
Teva Pharmaceuticals has received an Abbreviated Approval (AP) for a supplement of Risedronate Sodium.
View detail
regulatoryJun 23, 2026
FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)
Application NDA022434. Sponsor: CIPLA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ARGATROBAN.
View detail
regulatoryJun 23, 2026
FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)
Application NDA209552. Sponsor: EUGIA PHARMA SPECLTS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ARGATROBAN.
View detail
regulatoryJun 23, 2026
FDA AP — LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (SUPPL)
Application NDA206473. Sponsor: HOSPIRA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: LINEZOLID.
View detail
regulatoryJun 23, 2026
FDA AP — DIVALPROEX SODIUM (SUPPL)
Application ANDA077567. Sponsor: MYLAN. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: DIVALPROEX SODIUM.
View detail
insightJun 23, 2026
Teva's Risedronate Sodium Approval Enhances Competitive Position in Osteoporosis Market
The FDA's grant of Abbreviated Approval for Teva's Risedronate Sodium supplement is significant as it strengthens Teva's competitive position in the osteoporosis market. Portfolio teams must evaluate the implications for market share and pricing strategies in response to this regulatory development. Regulatory context from FDA (FDA AP — RISEDRONATE SODIUM (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (4 high-relevance).
View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Executive insights surface 1 risk-calibrated assessments for portfolio review. 5 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 1 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)
77%
Application NDA022434. Sponsor: CIPLA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ARGATROBAN.
Source: FDA
View evidence
FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)
77%
Application NDA209552. Sponsor: EUGIA PHARMA SPECLTS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ARGATROBAN.
Source: FDA
View evidence
FDA AP — LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (SUPPL)
77%
Application NDA206473. Sponsor: HOSPIRA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: LINEZOLID.
Source: FDA
View evidence
FDA AP — DIVALPROEX SODIUM (SUPPL)
66%
Application ANDA077567. Sponsor: MYLAN. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: DIVALPROEX SODIUM.
Source: FDA
View evidence
FDA AP — RISEDRONATE SODIUM (SUPPL)
66%
Application ANDA077132. Sponsor: TEVA PHARMS USA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: RISEDRONATE SODIUM.
Source: FDA
View evidence
Teva's Risedronate Sodium Approval Enhances Competitive Position in Osteoporosis Market
55%
The FDA's grant of Abbreviated Approval for Teva's Risedronate Sodium supplement is significant as it strengthens Teva's competitive position in the osteoporosis market. Portfolio teams must evaluate the implications for market share and pricing strategies in response to this regulatory development. Regulatory context from FDA (FDA AP — RISEDRONATE SODIUM (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (4 high-relevance).
Source: Humanexa Insight
View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

FDA Grants AP Status for Teva's Risedronate Sodium Supplement
Regulatory Approval

Insights

Teva's Risedronate Sodium Approval Enhances Competitive Position in Osteoporosis Market
Osteoporosis · Bisphosphonate

Companies

Teva
25 signals

Executive Summary

Key Developments

FDA Grants AP Status for Teva's Risedronate Sodium Supplement

FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)

FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)

FDA AP — LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (SUPPL)

FDA AP — DIVALPROEX SODIUM (SUPPL)

Teva's Risedronate Sodium Approval Enhances Competitive Position in Osteoporosis Market

Strategic Implications

Supporting Evidence

FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)

FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)

FDA AP — LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (SUPPL)

FDA AP — DIVALPROEX SODIUM (SUPPL)

FDA AP — RISEDRONATE SODIUM (SUPPL)

Teva's Risedronate Sodium Approval Enhances Competitive Position in Osteoporosis Market

Related Intelligence

Signals

Insights

Companies